

Mumbai, May 6, 2016

Wockhardt Q4FY16 Net Sales at Rs.1013 crore and PAT grew by 26% at Rs.43 crore

	Q4-FY16	Q4-FY15	Gwth	FY15-16	FY14-15	Gwth
	Jan - Mar	Jan - Mar	Y.O.Y	Apr - Mar	Apr - Mar	Y.O.Y
	2016	2015		2016	2015	
	Rsc	Rsc		Rsc	Rsc	
Sales	1,013	1,079	-6%	4,461	4,481	-
EBITDA *	74	136	-46%	518	827	-37%
EBITDA Margins %	7.3%	12.6%		11.6%	18.5%	
Profit After Tax	43	34	26%	326	405	-20%
PAT Margins %	4.2%	3.2%		7.3%	9.0%	
EPS	3.9	3.1		29.5	36.8	
* EBITDA excl "one offs & R&D"	147	176	-17%	708	752	-6%
EBIDTA % to Sales	14.5%	18.2%		17.1%	19.2%	

Wockhardt Limited, the Pharmaceutical and Biotechnology major, reported its 4th Quarter and Financial Year 15-16, today.

Emerging market business of the Company grew 59% during the quarter & 36% year on year. India business continued to display strong performance with 16% growth year on year and launched 48 new products. UK business (excluding one-time opportunity) grew by 15% in FY15-16 and 40% in Q4FY16.

During the Year, the Company received Qualified Infectious Disease Product (QIDP) status for its Breakthrough drug discovery programme in antibiotics for further three of its drugs namely WCK 4873, WCK 4282 and WCK 5222. During FY 14-15, Wockhardt received approval for WCK 771 and WCK 2349. Wockhardt is currently the only company globally to receive QIDP status for 5 drugs from US FDA.

The company received 2 approvals in US and have filed 17 ANDA's with US FDA during FY15-16 taking it to total of 84 ANDA's pending for approval as on date. The Company made 2 new fillings and received 10 new approvals in UK during FY15-16.

The company continued its pursuit of creating a strong Intellectual Property (IP) base and filed 43 patents during the Quarter ended 31st March, 2016 taking the cumulative filings to 2579. The company was granted 10 patents during the quarter and now totally holds 441 patents.

Year ended 31st March, 2016

Consolidated revenue for FY15-16 was Rs.4,461 crore and Profit After Tax was at Rs.326 crore. International Business contributed 68% of the Total Revenues during the FY15-16.

EBITDA excluding one-time opportunities and before R&D spend was Rs 708 crore (Margin at 17% to sales) compared to Rs 752 crore (Margin at 19% to sales) in the previous year.

The company continued to focus in Research & Development with yearly spent at Rs.498 crore (11% to sales) and including capital expenditure is at 15% to sales for the year ended FY16.

Capital expenditure of Rs.491 crore was incurred in FY15-16.

US Business contributed 22% of the Global Revenues.

The Irish Business grew by 5% in € terms (de-growth of 6% in INR terms) in FY15-16.

Quarter ended 31st March, 2016

Consolidated revenue for the quarter was at Rs.1,013 crore and PAT at Rs.43 crore.

6 new products were launched during the quarter in India.

EBITDA excluding one-time opportunities and before R&D spend was Rs 147 crore (Margin at 15% to sales) compared to Rs 176 crore (Margin at 18% to sales) in corresponding previous period.

The Company continued its focus on R&D and Research expenses stood at Rs.73 crore for the quarter representing 7% of sales.

The UK Business (excluding one-time opportunity) grew by 40% and stood at £ 28 Mn.

PRESS RELEASE

WOCKHARDT

**LIFE
WINS**

Wockhardt Limited

| D-4, MIDC, Chikalthana |

| Aurangabad |

| Maharashtra | | 431 006 |

| India |

| Tel.: +91-22-2653 4444 |

| www.wockhardt.com

Wockhardt's US Business contributed 22% of the Global Revenues in Q4FY16.

The Irish Business remained flat in € terms (de-growth by 8% in INR terms) in Q4FY16.

About Wockhardt :

Wockhardt is a Research based and technology intensive global pharmaceutical and biotechnology company. It's multi-disciplinary and innovative R&D programmes globally, are strongly focused on creating Intellectual Properties. It has 3 research centres globally and manufacturing facilities across India, USA, UK and Ireland. Wockhardt has a significant presence in USA, Europe and India, with 68% of its global revenues coming from international businesses. With a large pool of Patents and Intellectual Property knowhow, Wockhardt is home to 850 scientists, of whom 100 are doctorates. In all, Wockhardt has 441 Patents granted worldwide. In biotechnology research, it has built competent 'Concept to Market' capability in all facets of development and manufacture of recombinant biopharmaceuticals. Wockhardt boasts of a multi-ethnic workforce from 21 different nationalities.